familial Idiopathic inflammatory myopathy

Variable symptoms usually include progressive muscle weakness. May present similarly to juvenile dermatomyositis, but progress to systemic involvement with death by 4 years of age. There may also be no systemic invlovement in adults , with progression similar to POLYMYOSITIS. OMIM: 160750

Also Known As:

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Disease Context: Research Results

Related Diseases

1.	Myocarditis (Carditis)
2.	Macular Edema
3.	COVID-19

Experts

1.	Aguilar Castillo, Sergio De Jesús: 1 article (04/2022)
2.	Camargo Coronel, Adolfo: 1 article (04/2022)
3.	Hernández Vázquez, José Ramiro: 1 article (04/2022)
4.	Hernández Zavala, Mario Raúl: 1 article (04/2022)
5.	Jiménez Balderas, Francisco Javier: 1 article (04/2022)
6.	Mandinabeitia Rodríguez, Pedro: 1 article (04/2022)
7.	Quiñones Moya, Horacio: 1 article (04/2022)
8.	Zamora Zarco, Sandy: 1 article (04/2022)
9.	Herings, Ron M C: 1 article (12/2002)
10.	Klungel, Olaf H: 1 article (12/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to familial Idiopathic inflammatory myopathy:

1.	Fibric Acids (Fibrates)IBA 12/01/2002 - "The expected number of statin- or fibrate-related idiopathic myopathy is low and observed numbers are even lower in the Netherlands. " 12/01/2002 - "Based on the estimated prevalence of lipid-lowering drug use in the Netherlands in 1998 (n = 520 800), we expected 60 cases of idiopathic myopathy due to hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) or fibric acid derivatives (fibrates). "
2.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/01/2002 - "The expected number of statin- or fibrate-related idiopathic myopathy is low and observed numbers are even lower in the Netherlands. " 12/01/2002 - "Based on the estimated prevalence of lipid-lowering drug use in the Netherlands in 1998 (n = 520 800), we expected 60 cases of idiopathic myopathy due to hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) or fibric acid derivatives (fibrates). "
3.	VaccinesIBA 04/01/2022 - "Although it´s not possible to confirm a direct correlation between the vaccine and the onset of the disease, we considered that there are enough data to suspect that this could be a trigger event and therefore should always be considered a possible cause for a case of inflammatory idiopathic myopathy."
4.	Messenger RNA (mRNA)IBA 12/16/1991 - "While interleukin-1-receptor mRNA was present in samples from non-failing hearts and those with idiopathic myopathy, it was absent from patients with inflammatory myocarditis, suggesting receptor mRNA down-regulation."
5.	Retinaldehyde (Retinal)IBA 09/01/2023 - "Retinal microvascular abnormalities, cotton wool-like lesions, and macular edema following COVID-19 in a patient previously vaccinated with AstraZeneca and idiopathic myopathy."
6.	Oxidoreductases (Dehydrogenase)IBA 12/01/2002 - "Based on the estimated prevalence of lipid-lowering drug use in the Netherlands in 1998 (n = 520 800), we expected 60 cases of idiopathic myopathy due to hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) or fibric acid derivatives (fibrates). "
7.	LipidsIBA 12/01/2002 - "Based on the estimated prevalence of lipid-lowering drug use in the Netherlands in 1998 (n = 520 800), we expected 60 cases of idiopathic myopathy due to hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) or fibric acid derivatives (fibrates). "
8.	Coenzyme A (CoA)IBA 12/01/2002 - "Based on the estimated prevalence of lipid-lowering drug use in the Netherlands in 1998 (n = 520 800), we expected 60 cases of idiopathic myopathy due to hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) or fibric acid derivatives (fibrates). "